6533b86efe1ef96bd12cbdee
RESEARCH PRODUCT
Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities.
Sebastian ZahnreichStephan GrabbeArnulf MayerCarmen LoquaiHeinz Schmidbergersubject
OncologyProto-Oncogene Proteins B-rafCancer Researchmedicine.medical_specialtyBRAF inhibitormedicine.medical_treatmentRadiation ToleranceTargeted therapy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicinemedicineCombined Modality TherapyHumansVemurafenibneoplasmsMelanomaProtein Kinase Inhibitorsbusiness.industryMelanomaDabrafenibGeneral Medicinemedicine.diseaseCombined Modality TherapyRadiation therapyOncology030220 oncology & carcinogenesisConcomitantMutationbusinessmedicine.drugdescription
The introduction of small molecule BRAFV600 kinase inhibitors represents a milestone in the targeted therapy of patients with metastatic melanoma by a significant increase in therapeutic efficacy in terms of overall and progression-free survival compared with conventional chemotherapy. Beside BRAFV600 inhibitor treatment, radiotherapy is a further mainstay for the therapy of metastatic melanoma and thus a concomitant or sequential application of BRAFV600 inhibitors and radiotherapy is inevitable. Recent reports show a significant radiosensitization of the irradiated healthy tissue in patients with melanoma after the combination of radiotherapy and BRAFV600 inhibitors, evoking concern in clinical practice. We review interactions of BRAFV600 inhibitors and radiation with regard to antitumor effects and an increased radiotoxicity in the healthy tissue.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-12-01 | Future oncology (London, England) |